phosphonoacetic acid has been researched along with Ovarian Neoplasms in 6 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stehman, FB | 2 |
| Ehrlich, CE | 1 |
| Muss, HB | 1 |
| Slavik, M | 1 |
| Bundy, B | 1 |
| Creasman, WT | 1 |
| Erlichman, C | 1 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 1 |
| Sharma, A | 1 |
| Straubinger, NL | 1 |
| Straubinger, RM | 1 |
| Yang, JL | 1 |
| Fernandes, DJ | 1 |
| Wheeler, KT | 1 |
| Capizzi, RL | 1 |
| Chan, TC | 1 |
| Howell, SB | 1 |
6 other studies available for phosphonoacetic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Peritoneo-cystic shunt for malignant ascites.
Topics: Ascites; Aspartic Acid; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Ovaria | 1984 |
A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study.
Topics: Adult; Aged; Aspartic Acid; Blood Cell Count; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm | 1984 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
Topics: Antineoplastic Agents; Aspartic Acid; Cell Division; Drug Carriers; Drug Compounding; Female; Humans | 1993 |
PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartic Acid; Bromodeoxyuridine; Cell Division; DN | 1996 |
Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Line; Dip | 1985 |